ACTC2019 FINAL PROGRAM
| 07:30 – 08:30 | Registration |
| 08:30 – 09:00 | Welcome Address Chairperson’s Opening Remarks |
| 09:00 – 12:30 |
PLENARY LECTURE SESSION 1 RECENT ADVANCES IN THE BIOLOGY OF METASTASIS Chairing: Evi Lianidou & Klaus Pantel
|
| 09:00 – 09:30 PL1-1 |
“Liquid Biopsy: Current clinical application and challenges” Klaus Pantel, University Medical Centre Hamburg Eppendorf, Hamburg, Germany |
| 09:30 – 10:00 PL1-2 |
“Epithelial mesenchymal transition in carcinoma; therapeutic intervention” Jean Paul Thiery, University Paris Denis Diderot, Paris, France |
| 10:00 – 10:30 PL1-3 |
“Stromal niches for bone metastasis” Yibin Kang, Princeton University, Princeton, New Jersey, USA |
| 10:30 – 11:00 | POSTER VIEWING AND NETWORKING COFFEE BREAK |
| 11:00 – 11:30 PL1-4 |
“About Chomsky, patterns, non-coding RNAs cell to cell communication and cancer metastases” George Calin, University of Texas MD Anderson Cancer Center, Houston, USA |
| 11:30 – 12:00 PL1-5 |
“Strategies to Exploit the Biology of Exosomes for Diagnosis and Treatment of Cancer” Raghu Kalluri, University of Texas MD Anderson Cancer Center, Houston, TX, USA |
| 12:00 – 12:30 PL1-6 |
“Tumor-educated platelets for the detection of cancer” Thomas Wurdinger, VU University Medical Center, Netherlands |
| 12:30 – 13:30 | LUNCH BREAK |
| 13:30 – 14:30 |
ORAL PRESENTATIONS SESSION 1 BASIC RESEARCH IN LIQUID BIOPSIES Chairing: Francoise Farace & Stefanie S. Jeffrey
|
| 13:30 – 13:40 O1-1 |
“Circulating tumor cells derived models as a tool for discovery and development of anti-cancer therapy” Nataša Stojanović1, Catherine Botteron1, Kathrin Weidele1, Steffi Treitschke1, Giancarlo Felicelo1, Florian Lueke2, Daniel Heudobler2, Christian Schulz3, Bernhard Braun4, Jan Braess4, Florian Weber5, Tobias Pukrop2, Bernhard Polzer1, Kamran Honarnejad1, Christian Werno1 and Christoph A. Klein1,6, 1Fraunhofer-Institute for Toxicology and Experimental Medicine, Division of Personalized Tumor Therapy, Regensburg, Germany, 2Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany, 3Department of Internal Medicine II, Pneumology, University Hospital Regensburg, Regensburg, Germany, 4Department for oncology and hemathology, Hospital Barmherzige Brüder, Regensburg, Germany, 5Institute of Pathology, University of Regensburg, Regensburg, Germany, 6Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany |
| 13:40 – 13:50 O1-2 |
“Circulating tumor microemboli correlates with platelet-to-lymphocyte ratio in patients with colon cancer stages II and III” E.A. Abdallah1, V. Souza e Silva2, R.M. Takahashi3, B.C.T.C.P. Flores1, A.C. Braun1, J.G.R. Tarazona1, V.S. Alves1, Milena Shizue Tariki2, L.T.D. Chinen1, 1International Research Center, A.C. Camargo Cancer Center, São Paulo, SP, Brazil, 2Department of Clinical Oncology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil, 3Department of Abdominal Surgery, A.C. Camargo Cancer Center, São Paulo, SP, Brazil |
| 13:50 – 14:00 O1-3 |
“Microtubule disruption reduces circulating tumor cell metastasis more effectively than primary tumor growth” Keyata N. Thompson1, Julia A. Ju1, Eleanor C.H. Ory1, Christopher M. Jewell2, and Stuart S. Martin1,3,4, 1Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine. 655 W. Baltimore St. Baltimore, MD 21201, USA, 2Department of Bioengineering, University of Maryland, College Park, MD, 3Department of Physiology, University of Maryland School of Medicine. 655 W. Baltimore St. Baltimore, MD 21201,USA, 4Graduate Program in Molecular Medicine, University of Maryland School of Medicine. 800 W. Baltimore St. Baltimore, MD 21201, USA |
| 14:00 – 14:10 O1-4 |
“The prognostic value of JUNB-positive CTCs in metastatic breast cancer; from bioinformatics to phenotypic characterization” Galatea Kallergi1,2, VasileiaTsintari3, Stelios Sfakianakis4, Ekaterini Bei5, Eleni Lagoudaki6, Anastasios Koutsopoulos6, Nefeli Zacharopoulou2, Saad Alkahtani2,7, Saud Alarifi2,7, Christos Stournaras2, Michalis Zervakis5 and Vassilis Georgoulias1, 1Laboratory of Τumor Cell Βiology, Medical School, University of Crete, Heraklion, Greece, Hellenic Oncology Research Group (HORG), Athens, Greece, 2Department of Biochemistry, Medical School, University of Crete, Heraklion, Greece, 3Department of Hematology,University Hospital of the Eberhard-Karls-University Tübingen, Germany, 4Computational BioMedicine Laboratory, Institute of Computer Science, Foundation for Research and Technology, Heraklion, Greece, <sup5Digital Image and Signal Processing Laboratory, School of Electrical and Computer Engineering, Technical University of Crete, Chania, Greece, 6Department of Pathology, University General Hospital of Heraklion, Crete, Greece, 7Department of Zoology, Science College, King Saud University, Riyadh, Saudi Arabia |
| 14:10 – 14:20 O1-5 |
“Dual-positive circulating tumor cells (DP-CTC): a new subpopulation of CTC supporting a role of cell-fusion in tumor progression” Carolina Reduzzi1 , Marta Vismara1 , Lorenzo Gerratana2,3, Marco Silvestri1, Filippo De Braud4,5, Francesco Raspagliesi6, Elena Verzoni4, Serena Di Cosimo1, Alessandro Gronchi6, Laura D. Locati4, Massimo Cristofanilli3, Maria Grazia Daidone1, Vera Cappelletti1, 1Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy, 2Department of Medicine (DAME), University of Udine, Italy, 3Department of Medicine-Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA, 4Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy, 5University of Milan, Milan, Italy, 6Department of surgery, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy |
| 14:20 – 14:30 O1-6 |
“Targeted proteomics reveal distinctive endothelial characteristics in a population of genomically-normal circulating rare cells previously identified in a castrate resistant prostate cancer patient” Carmen Ruiz1, Serena Zheng1, Michael Morikado1, Paymaneh Malihi1, Angel E. Dago2, Mitchell E. Gross3, James Hicks1 and Peter Kuhn1, 1Michelson Center for Convergence Bioscience, University of Southern California, Los Angeles, CA 90089 USA, 2Epics Sciences, Inc, San Diego, CA 92121 USA, 3Keck School of Medicine, University of Southern California, Los Angeles, CA 90089 USA |
| 14:30 – 15:40 |
INDUSTRY SPONSORED ORAL PRESENTATIONS Chairing: Nikolas Stoecklein & Thomas Schlange
|
| 14:30 – 15:00 |
Menarini Silicon Biosystems (Platinum Sponsor) “Advances in CTCs isolation and molecular characterization with single-cell resolution” Nicolò Manaresi, PhD, Chief Scientific Officer |
| 15:00 – 15:10 | QIAGEN (Silver sponsor) “Multimodal analysis of RNA from circulating tumor cells, ccfDNA and genomic DNA in a single blood sample” Anna Babayan, PhD |
| 15:10 – 15:20 | RareCells (Silver sponsor) “Marker-independent CTC detection in diagnostic leukapheresis product from patients with non-small cell lung cancer” Menno Tamminga, PhD |
| 15:20 – 15:30 | Celsee (Silver sponsor) “Combined Single Cell Analysis of Solid Tumors and CTCs for Comprehensive Patient Management” Bruce K. Patterson, MD, CEO and Founder, IncellDx Inc |
| 15:30 – 15:40 | Novosanis (Silver sponsor) “Urine as a Liquid Biopsy” Quinten Van Avondt, Novosanis NV, Wijnegem, Belgium |
| 15:40 – 16:30 | POSTER SESSION 1 AND NETWORKING COFFEE BREAK |
| 16:30 – 18:00 |
PLENARY LECTURE SESSION 2 NEW INSIGHTS ON THE POTENTIAL OF LIQUID BIOPSY Chairing: Jean-Paul Thiery & Alberto Bardelli
|
| 16:30 – 17:00 PL2-1 |
“Organs-on-a-chip Technology and Single Cell Drug Testing” Stefanie S. Jeffrey, Stanford University, School of Medicine, Stanford, USA |
| 17:00 – 17:30 PL2-2 |
“Clinical Utility of Monitoring ctDNA and miRNA in Metastatic Melanoma Progression” Dave Hoon, John Wayne Cancer Institute, Santa Monica, USA |
| 17:30 – 18:00 PL2-3 |
“Tracking colorectal cancer evolution” Alberto Bartelli, Univ of Torino- Candiolo Cancer Institute, Torino, Italy |
| 18:00 – 21:00 | WELCOME RECEPTION |
| 08:30 – 09:30 |
PLENARY LECTURE SESSION 3 LIQUID BIOPSY IN CLINICAL PRACTICE Chairing: Massimo Cristofanilli & Jean-Yves Pierga
|
| 08:30 – 09:00 PL3-1 |
“Advancing Liquid Biopsy in the precompetitive space – lessons-learned from the IMI public-private partnership CANCER-ID” Thomas Schlange, Bayer Pharma, Germany |
| 09:00 – 09:30 PL3-2 |
“Liquid biopsies as a potential therapeutic tool in head and neck cancer” Amanda Psyrri, University of Athens Medical School, Athens, Greece |
| 09:30 – 10:00 PL3-3 |
“Liquid Biopsy in early breast cancer – is there any clinical utility?” Wolfgang Janni, University of Ulm, Germany |
| 10:00 – 10:30 PL3-4 |
“Liquid biopsy for precision medicine in breast cancer: challenges and opportunities” Michail Ignatiadis, Jules Bordet Institute Brussels, Belgium |
| 10:30 – 11:00 |
POSTER VIEWING SESSION 1 AND NETWORKING COFFEE BREAK
|
| 11:00 – 11:30 PL3-5 |
“ctDNA in breast cancer management” Carlos Caldas, MD, PhD, University of Cambridge, Cambridge, UK |
| 11:30 – 12:00 PL3-6 |
“Liquid Biopsy in MBC: Recognizing The Bad, The Good and the Ugly” Massimo Cristofanilli, Robert H Lurie Comprehensive Cancer Center Feinberg School of Medicine, Chicago, USA |
| 12:00 – 12:30 PL3-7 |
“Clinical utility of CTC and ctDNA in breast cancer” Jean-Yves Pierga, Institute Curie and University Paris Descartes, Paris, France |
| 12:30 – 13:30 |
LUNCH BREAK
|
| 13:30 – 14:30 |
ORAL PRESENTATIONS SESSION 2 CTCs CLINICAL APPLICATIONS Chairing: Wolfgang Janni & Michail Ignatiadis
|
| 13:30 – 13:40 O2-1 |
“Is liquid biopsy ready for personalized medicine in head and neck cancers?” Chamindie Punyadeera1, 1The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, QueenslandUniversity of Technology, Kelvin Grove, QLD, Australia, 2Translational Research Institute,Woolloongabba, Australia |
| 13:40 – 13:50 O2-2 |
“Standardizing a PD-L1 assay suitable for circulating tumor cells (CTCs)” Elisabetta Rossi1,2, Rita Lampignano3*, Riccardo Vidotto2, Maria Chiara Scaini2,Vera Kloten3, Kevin Leone2, Thomas Schlange3, Rita Zamarchi2, 1Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy, 2Veneto Instituteof Oncology IOV-IRCCS, Padua, Italy, 3Bayer AG, Research & Development, Pharmaceuticals,Wuppertal, Germany. *Current Address: Miltenyi Biotec GmbH, Bergisch Gladbach, Germany |
| 13:50 – 14:00 O2-3 |
“Circulating tumor cells and sentinel lymph node burden in stage III melanoma patients” Carolyn Hall, PhD1, Vanessa Sarli, BS1, Joshua Upshaw, BS1, Salyna Meas, BS1, Fuchenchu Wang, MS3, Yisheng Li, PhD3, Merrick Ross, MD2, and Anthony Lucci,MD1, 1The Departments of Breast Surgical Oncology, 2Surgical Oncology, and 3Biostatsistics, The Universityof Texas MD Anderson Cancer Center, Houston, TX |
| 14:00 – 14:10 O2-4 |
“The whole transcriptional landscape of circulating tumor cells compared to metastases in stage IV breast cancer” Alexander Ring1, Daniel Campo2, Tania B. Porras3, Pushpinder Kaur3, Victoria A.Forte4, Debu Tripathy5, Janice Lu6, Irene Kang6, Michael F. Press7, Anson Snow3Yue Zhu3, Ryan Brankovic3, Gabriel Zada8, Naveed Wagle6, Julie E. Lang3, 1Department of Hematology and Oncology, University Hospital Zurich, Zurich, Switzerland, 2Department of Biological Sciences, University of Southern California, Los Angeles, CA, USA, 3Sectionof Surgical Oncology, Department of Surgery and University of Southern California Norris CancerCenter, University of Southern California, Los Angeles, CA, USA, 4Division of Medical Oncology,Department of Medicine, Maimonides Medical Center, NY York, NY, USA, 5Department of BreastMedical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA, 6Division of Medical Oncology,Department of Medicine and University of Southern California Norris Cancer Center, University ofSouthern California, Los Angeles, CA, USA, 7Department of Pathology and University of SouthernCalifornia Norris Cancer Center, University of Southern California, Los Angeles, CA, USA, 8Departmentof Neurosurgery and University of Southern California Norris Cancer Center, University of SouthernCalifornia, Los Angeles, CA, USA |
| 14:10 – 14:20 O2-5 |
“Randomized phase III study comparing Folfox + Bevacizumab vs Folfoxiri + Bevacizumab (BEV) as 1st line treatment in patients withmetastatic colorectal cancer (MCRC) with ≥3 baseline circulating tumorcells (bCTCs)” M. Benavides1, V. Alonso2, R. Dueñas3, J.M. Campos4, P. Salinas5, C. Montagut6, A. Ruiz Casado7, J. Muñoz8, M. Gil Raga9, F. J. González10, B. Massutí11, A. López-Ladrón12, J. Aparicio13, M. Marín14, J. Alfaro15, M. Zanui16, D. GutiérrezAbad17, A. Ma García Tapiador18, C. García-Girón19, J. Molina Saera20, E. Torres Sánchez21, I. López22, C. Bosch23, A. Arrivi23, A. Salud25, 1H. Universitario Regional y Virgen de la Victoria (Málaga), 2H. Universitario Miguel Servet (Zaragoza), 3H. Ciudad de Jaén, 4H. Arnau de Vilanova (Valencia), 5H. La Zarzuela (Madrid), 6H. del Mar, MedicalResearch Institute, CIBERONC (Barcelona), 7H. Puerta de Hierro (Madrid), 8H. San Pedro de Alcántara(Cáceres), 9H. de Sagunto (Valencia), 10H. Universitario Quirón (Madrid), 11H. General Universitario(Alicante), 12H. Nuestra Señora de Valme (Sevilla), 13H. Universitario y Politécnico La Fe (Valencia), 14H. Virgen de la Arrixaca (Murcia), 15C. Sanitari de Terrasa (Barcelona), 16H. de Mataró (Barcelona), 17H. de Fuenlabrada (Madrid), 18C. H. La Mancha Centro (Ciudad Real), 19H. Universitario de Burgos, 20H. Provincial (Castellón), 21H. C. Univ. Virgen de la Victoria (Málaga), 22H. Can Misses (Ibiza), 23H.Dr. Peset (Valencia), 24C. Rotger (Palma de Mallorca), 25H. de Lleida Arnau de Vilanova (Lleida) |
| 14:20 – 14:30 O2-6 |
“Diagnostic leukapheresis increases detection rate of circulating tumor cells in non-small cell lung cancer patients” Menno Tamminga1, Kiki C. Andree2, Hilda van den Bos3, T. Jeroen N. Hiltermann1, Anouk Mentink2, Diana Spierings3, Peter Lansdorp3, Ed Schuuring4, Leon W. M. M. Terstappen2, Harry J. M. Groen1, 1Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, the Netherlands, 2Department of Medical Cell BioPhysics, Faculty of Sciences and Technology,University of Twente, Enschede, the Netherlands, 3European Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, the Netherlands, 4Departmentof Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, the Netherlands |
| 14:30 – 15:40 |
INDUSTRY SPONSORED ORAL PRESENTATIONS Chairing: Catherine Alix-Panabières & Evi Lianidou
|
| 14:30 – 15:00 |
ANGLE (Gold Sponsor) “Isolation and Molecular Characterization of Circulating Tumor Cells” M. C. Scheidmann, University of Basel and University Hospital Basel, Switzerland |
| 15:00 – 15:20 |
ALS – Tokyo Ohka Kogyo (Silver Sponsors) “Longitudinal analysis of CTCs obtained from a breast cancer index patient” André Franken1, Bianca Behrens2, Liwen Yang1, Mahdi Rivandi1, Nikolas H. Stoecklein2, Dieter Niederacher1, Tanja Fehm, Hans Neubauer 1Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the HeinrichHeine University Duesseldorf, Duesseldorf, Germany, 2General, Visceral and Pediatric Surgery, University Hospital and Medical Faculty of the Heinrich Heine University Duesseldorf, Duesseldorf, Germany |
| 15:20 – 15:30 |
RareCyte (Silver Sponsor) “A discovery and testing platform for analysis of liquid and tissue biopsies” E. Kaldjian, MD |
| 15:30 – 15:40 |
Gilupi (Silver Sponsor) “Combination of in vivo CTC isolation and in situ Padlock probe technology for mRNA detection” A. El-Heliebi1,2, Thomas Kroneis1, Martina Vetter3, Christoph Thomssen3 1Gottfried Schatz Research Center for Cell Signaling, Metabolism & Aging, Department of Cell Biology,Histology and Embryology, Medical University Graz, Austria, 2Center for Biomarker Research inMedicine (CBmed), Graz, Austria, 3Universitätsklinikum Halle (Saale) Universitätsklinik und Poliklinik Für Gynäkologie |
| 15:40 – 16:30 |
POSTER VIEWING SESSION 2 AND NETWORKING COFFEE BREAK
|
| 16:30 – 17:00 |
TRAVEL AWARD ORAL PRESENTATIONS Chairing: Caroline Dive
|
| 16:30 – 16:40 OTA-1 |
“Isolation, characterization and expansion of circulating tumor cells” Arutha Kulasinghe1,6, Joanna Kapeleris1,6, Liz Kenny2, Majid Warkiani3, Ian Vela4,6, Jean-Paul Thiery5, Ken O’Byrne1,6, Chamindie Punyadeera1,6 1The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, QLD, Australia, 2School of Medicine, University of Queensland, Royal Brisbane and Women’s Hospital, Brisbane, Central Integrated Regional Cancer Services, Queensland Health, QLD, Australia, 3School of Biomedical Engineering, University of Technology Sydney, NSW, Australia, 4Australian Prostate Cancer Research Center Queensland / Queensland University of Technology, Translational Research Institute, Brisbane, QLD, Australia, 5Comprehensive Cancer Centre Institut Gustave Roussy, Vilejuif, France, 6Translational Research Institute, Woolloongabba, Australia |
| 16:40 – 16:50 OTA-2 |
“Monitoring of BRCA1 promoter hypermethylation in circulating tumorDNA (ctDNA) to detect therapy resistance” Maha Elazezy1, Katharina Prieske2, Lan Kluwe3, Okka Wilken1, Volkmar Müller2, Barbara Schmalfeldt2, Klaus Pantel1, and Simon A. Joosse1 1Department of Tumor Biology, 2Department of Gynecology, 3Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany |
| 16:50 – 17:00 OTA-3 |
“Patterns and dynamics of genome instability drive the metastaticactivity in non-small cell lung cancer (NSCLC) circulating tumor cell(CTC)-derived xenograft (CDX) models” Tala Tayoun1,2,3*, Vincent Faugeroux1,2*, Emma Pailler1,2, Marianne Oulhen1,2, Olivier Deas4, Laura Mezquita5, Laura Brulle-Soumare4, Stefano Cairo4, Jean-YvesScoazec6, Virginie Marty6, Maud NgoCamus5, Claudio Nicotra5, David Planchard5,Patricia Kannouche7, Benjamin Besse5, Jean-Gabriel Judde4, Patrycja Pawlikowska2, Françoise Farace1,2 1Gustave Roussy, Université Paris-Saclay, “Circulating Tumor Cells” Translational Platform, CNRSUMS3655 – INSERM US23AMMICA, F-94805, VILLEJUIF France; 2INSERM, U981 “Identification of Molecular Predictors and new Targets for Cancer Treatment”, F-94805, VILLEJUIF France; 3Univ ParisSud, Université Paris-Saclay, Faculty of Medicine, F-94270, LE KREMLIN-BICETRE France; 4XenTech, F-91000, EVRY France; 5Gustave Roussy, Université Paris-Saclay, Department of Cancer Medicine, F-94805, VILLEJUIF France; 6Gustave Roussy, Université Paris-Saclay, “Histo-Cytopathology” Translational Platform, CNRS UMS3655 – INSERM US23 AMMICA, F-94805, VILLEJUIF France; 7University of Paris-Sud, INSERM U8200 “Stabilité génétique et oncogenèse”, Gustave Roussy, VILLEJUIF France, *Both authors contributed equally to the study |
| 17:00 – 18:00 |
PLENARY LECTURE SESSION 5 LIQUID BIOPSY: RECENT PROGRESS IN LUNG CANCER Chairing: Peter Kuhn
|
| 17:00 – 17:30 PL4-1 |
“What’s next for lung cancer CTCs?” Caroline Dive, University of Manchester, UK |
| 17:30 – 18:00 PL4-2 |
“Therapeutic resistance and tumor heterogeneity unraveled by single-CTC analysis and CDX models” Francoise Farace, Gustave Roussy, Villejuif, France |
|
FREE EVENING – FACULTY DINNER
|
|
| 08:30 – 12:30 |
PLENARY LECTURE SESSION 6 RECENT ADVANCES ON THE ISOLATION, ENUMERATION AND MOLECULAR CHARACTERIZATION OF CTCs Chairing: Leon Terstappen & Catherine Alix-Panabières
|
| 08:30 – 09:00 PL5-1 |
“Mathematical oncology to integrate clinical and liquid biopsy data for the prediction of survival” Peter Kuhn, USC Michelson Center, Los Angeles, CA, USA |
| 09.00 – 09.30 PL5-2 |
“PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via Nodal/Notch/Nodal Signalling” Dario Marchetti, Professor, Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA |
| 09:30 – 10:00 PL5-3 |
“Circulating Tumor Cells (CTCs) and tumor derived Extracellular Vesicles (tdEVs)” Leon Terstappen, University of Twente, the Netherlands |
| 10:00 – 10:30 PL5-4 |
“Circulating Tumor Cell Capture, Interrogation, Imaging, Automated Analysis and Culture: New Tools and Biologic Insights” Richard J. Cote, Washington University in St Louis, St Louis, USA |
| 10:30 – 11:00 |
POSTER VIEWING SESSION 1 AND NETWORKING COFFEE BREAK
|
| 11:00 – 11:30 PL5-5 |
“Circulating Tumor Cells: Finding Rare Events for A Huge Knowledge of Cancer Dissemination” Catherine Alix-Panabieres, CHRU Montpellier, France |
| 11:30 – 12:00 PL5-6 |
“CTC-based liquid biopsies and Diagnostic Leukapheresis” Nikolas Stoecklein, Heinrich Heine University, Dusseldorf, Germany |
| 12:00 – 12:30 PL5-7 |
“Molecular characterization of single circulating tumor cells in breast and ovarian cancer” Sabine Kasimir-Bauer, University Hospital of Essen, Essen, Germany |
| 12:30 – 13:30 |
LUNCH BREAK
|
| 13:30 – 14:30 |
ORAL PRESENTATIONS SESSION 3 NOVEL TECHNOLOGIES IN LIQUID BIOPSIES Chairing: Richard J. Cote & Sabine Kasimir-Bauer
|
| 13:30 – 13:40 O3-1 |
“Decoding circulating tumor cell heterogeneity: an integrated approach combining advanced microfluidics, quantitative imaging and machine learning” Majid Ebrahimi Warkiani, School of Biomedical Engineering, Center for Health Technologies, University of Technology Sydney, Sydney, Ultimo NSW 2007, Australia |
| 13:40 – 13:50 O3-2 |
“Using the cancer-targeting malarial VAR2CSA protein for both capture and detection of circulating glioma cells” Sara Bang-Christensen1, Rasmus S. Pedersen1, Marina A. Pereira1, Thomas M. Clausen1, Caroline B. Løppke1, Nicolai T. Sand1, Louise Goksøyr1, Swati Choudhary1, Adam F. Sander1, Mathias H. Torp2, Thor Theander1, Olga Østrup2, Ulrik Lassen3, Petra Hamerlik4, Ali Salanti1, Mette Ø. Agerbæk1, 1Center for Medical Parasitology at Department of Immunology and Microbiology, University of Copenhagen and Department of Infectious Diseases, Copenhagen University Hospital, Copenhagen, Denmark, 2Center for Genomic Medicine, Rigshospitalet, Copenhagen University, Copenhagen, Denmark, 3Department of Oncology, Copenhagen University, Rigshospitalet, Copenhagen, Denmark, 4Danish Cancer Society Research Center, Copenhagen, Denmark |
| 13:50 – 14:00 O3-3 |
“Two-tailed PCR for precision diagnostics” Mikael Kubista, Robert Sjöback, Andrei Herdean, Alexandra Bergman, Peter Androvic, Lukas Valihrach, TATAA Biocenter, Sweden, Institute of Biotechnology, Czech Academy of Science |
| 14:00 – 14:10 O3-4 |
“Microfluidic systems for rapid single cell profiling and in vivo isolation of CTCs” Tae Hyun Kim1,2,3, Sarah Owen1,3, Ting-Wen Lo1,3, Yang Wang1,3, Shamileh Fouladdel3,7, Mina Zeinali1,3, Evan Keller3,7, Ryan Oliver4, Douglas H. Thamm5, Laura Cooling6, Costanza Paoletti7,Kaylee Smith1, Ebrahim Azizi7, Nithya Ramnath7 and Daniel F. Hayes7*, Sunitha Nagrath*1,3,7, 1Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA, 2Department of Electrical Engineering and Computer Science, University of Michigan, Ann Arbor, MI, USA, 3Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA, 4Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA, 5Flint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA, 6Departmentof Pathology, University of Michigan, Ann Arbor, MI, USA, 7Department of Internal Medicine, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA |
| 14:10 – 14:20 O3-5 |
“Highly recurrence prognostic of colorectal cancer via dual-indicators from microfluidic counted CTCs and CEA level” Chun-Jieh Hsu1, Hsueh-Yao Chu1, Chun-Wei Lee1, Bing Hao Yeh1, Long-Sheng Lu2*, Jeng-KaiJiang3 and Fan-Gang Tseng1,4,5,*, 1Department of Engineering and System Science, National Tsing Hua University, Taiwan, ROC, 2Department of Radiation Oncology, Taipei Medical University Hospital, Taipei Taiwan ROC, 3Division of Colorectal Surgery, Department of Surgery, Veterans General Hospital-Taipei, Taipei 11217, Taiwan, 4Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu, Taiwan ROC, 5Research Center for Applied Sciences, Academia Sinica, Taipei, Taiwan ROC |
| 14:20 – 14:30 O3-6 |
“Automated classification of circulating tumor cells by deep learning” Leonie L. Zeune1, Yoeri E. Boink2,3, Guus van Dalum4, Afroditi Nanou1, Sanne de Wit1, Kiki C.Andree1, Joost F. Swennenhuis1, Leon Terstappen1, Christoph Brune2, 1Medical Cell BioPhysics, University of Twente, Enschede, The Netherlands, 2Applied Mathematics, University of Twente, Enschede, the Netherlands, 3Biomedical Photonic Imaging, University of Twente, Enschede, the Netherlands, 4General,Visceral and Pediatric Surgery, University Hospital and Medical Faculty of the Heinrich-Heine-University, Duesseldorf,Germany |
| 14:20 – 14:30 |
INDUSTRY SPONSORED ORAL PRESENTATIONS Chairing: Dave Hoon & Michael Speicher
|
| 14:30 – 15:00 |
Biomolecular Systems (Platinum Sponsor) “Evaluation of Cooperative Primers for Rare Allele Detection” Dr Jana Kent, CEO, CoDiagnostics Inc |
| 15:00 – 15:30 |
Agena Bioscience (Gold Sponsor) “Impact on treatment decisions in Advanced Non-Small Cell Lung Cancer depending on method sensitivity for Liquid Biopsy Testing” Dr. Pierre-Jean Lamy, Imagenome, Montpellier, France |
| 15:30 – 16:30 |
POSTER VIEWING SESSION 3 AND NETWORKING COFFEE BREAK
|
| 16:30 – 18:00 |
PLENARY LECTURE SESSION 6 LIQUID BIOPSIES: RECENT ADVANCES ON PROSTATE CANCER Chairing: Emmanuel Antonarakis & Howard Scher
|
| 16:30 – 17:00 PL6-1 |
“Dissecting the molecular profiles of circulating tumor cells in xenograft models of prostate cancers” Erik Thomson, Queensland University of Technology, Brisbane, Australia |
| 17:00 – 17:30 PL6-2 |
“Using liquid biopsy as a treatment-selection tool in advanced prostate cancer” Emmanuel Antonarakis, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, USA |
| 17:30 – 18:00 PL6-3 |
“The Evaluation of Pre-analytic Variables on “Liquid Biopsy” Testing for Prostate Cancer: Information Everybody Wants but Nobody Wants to Pay For” Howard Scher, Memorial Sloan Kettering Cancer Research, New York, USA |
| 20:00 |
GALA DINNER PARTY
|
| 08:30 – 09:30 |
ORAL PRESENTATIONS SESSION 4 NOVEL TECHNOLOGIES IN LIQUID BIOPSIES Chairing: Dario Marchetti & Mike Makrigiorgos
|
| 08:30 – 08:40 O4-1 |
“CTCs isolation using VyCAP, DEPArray and micromanipulation for single cell analysis” Thais Pereira-Veiga1, Carmen Abuin1, Ramesh Gandusekar1, Joska Broekmaat2, Lisa Oomens2, Arjan Tibbe2, Gema Moreno3, Rafael López-López1,4,5, Laura Muinelo-Romay4,5 and Clotilde Costa1,4, 1Roche-Chus Joint Unit. University Hospital of Santiago, Santiago de Compostela, Spain, 2VyCAP BV, Enschede, the Netherlands., 3Fundación MD Anderson, Madrid, Spain, 4CIBERONC, Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain, 5Liquid Biopsy Analysis Unit, Oncomet, Health Research Institute of Santiago, University Hospital of Santiago, Santiago de Compostela, Spain |
| 08:40 – 08:50 O4-2 |
“A flow-cytometric label-free and low-cost method for isolation of viable CTC in NSCLC patients” Matteo Turetta1, Michela Bulfoni2, Giulia Brisotto1, Macerelli Marianna2, Francesco Cortiula3, Gianpiero Fasola2, De Maglio Giovanna2, Pizzolitto Stefano2, Zanello Andrea3, Biscontin Eva1, Mariuzzi Laura2,3, Agostino Steffan1, Carla DiLoreto2,3, Daniela Cesselli2,3 and Fabio Del Ben3, 1Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Italy, 2Udine Academic Hospital, Udine, Italy, 3Department of Medicine, University of Udine, Udine, Italy |
| 08:50 – 09:00 O4-3 |
“Comprehensive characterization of cell-free tumor DNA in plasma and urine reveals renal cell carcinoma as low ctDNA tumor type of patients with renal tumor” Tina Moser1, Christopher G Smith2,3, Maximilian Seles4, Martin Pichler5, Gabriel Wcislo6, Matthew Eldridge2,3, Florent Mouliere2,3, Katrin Heider2,3, Anne Warren7, Nitzan Rosenfeld2,3, Grant D Stewart7,8, Ellen Heitzer1,9, 1Medical University of Graz, Diagnostic and Research Center for Molecular Biomedicine, Institute of Human Genetics, Austria, 2Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, 3Cancer Research UK Major Centre – Cambridge, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB20RE, 4Medical University of Graz, Department of Urology, Graz, Austria Medical University of Graz, 5Department of Internal Medicine Graz, Austria Division of Oncology, Graz Austria, 6Military Institute of Medicine, Department of Oncology, Warsaw,Poland, 7Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK, 8Department of Surgery, University of Cambridge, Cambridge CB2 0QQ, UK, 9Christian Doppler Laboratory for Liquid Biopsies for early Detection of Cancer, Austria |
| 09:00 – 09:10 O4-4 |
“Multi-omic profiling of cancer cells, cell-free-, and exosome-derived DNA isolated from the cerebrospinal fluid of pediatric brain cancer patients” Miodrag Gužvić1, Giancarlo Feliciello2, Zbigniew T. Czyz2, Marcus Jakob3, Markus J. Riemenschneider4, Selim Corbacioglu3, Bernhard Polzer2, Christoph A. Klein1,2, 1Chair of Experimental Medicine and Therapy Research, University of Regensburg, Regensburg,Germany; 2Division of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, Germany; 3Department of Pediatric Hematology, Oncology & Stem Cell Transplantation, University of Regensburg, Regensburg, Germany; 4Department of Neuropathology, University Hospital Regensburg, Regensburg, Germany |
| 09:10 – 09:20 O4-5 |
“Multicenter evaluation of ccfDNA extraction and downstream analyses for the development of standardized (pre)-analytical workflows” Rita Lampignano1,*, Martin H.D. Neumann1,*, Sabrina Weber2,3, Vera Kloten1, Andrei Herdean4, Thorsten Voss5, Daniel Groelz5, Anna Babayan6, Marco Tibbesma7, Martin Schlumpberger8, Francesca Chemi9, Dominic G. Rothwell9, Harriet Wikman6, Jean-Pierre Galizzi10, Inger Riise Bergheim11, Hege Russnes11, Benedetta Mussolin12, Serena Bonin13, Christine Voigt15, Hanny Musa16, Pamela Pinzani17, Evi Lianidou14, Ged Brady9, Michael R. Speicher2, Klaus Pantel6, Fay Betsou18, Ed Schuuring7, Mikael Kubista4, Wim Ammerlaan18, Markus Sprenger-Haussels8, Thomas Schlange1,#, Ellen Heitzer2,3,#,¶ for the IMI CANCER-ID consortium, *Both authors contributed equally; #Both authors contributed equally; ¶Corresponding author 1Bayer AG, Precision Medicine Markers, Wuppertal, Germany, 2Institute of Human Genetics, Diagnostic & Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria, 3Christian Doppler Laboratory for Liquid Biopsies for Early Detection of Cancer, Medical University of Graz, Graz, Austria, 4TATAA Biocenter Ab, Gothenburg, Sweden, 5PreAnalytiX GmbH, Hombrechtikon, Switzerland, 6University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 7University of Groningen, University Medical Center of Groningen, the Netherlands, 8QIAGEN GmbH, Hilden, Germany, 9CR-UK Manchester Institute, University of Manchester, UK, 10Servier, Suresnes, France, 11Department of Cancer Genetics, Institute of Cancer Research, Oslo University Hospital, Oslo, Norway, 12Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy, 13University of Trieste, DSM- Cattinara Hospital, Trieste, Italy, 14University of Athens, Athens, Greece, 15Alacris Theranostics GmbH, Berlin, Germany, 16Boehringer-Ingelheim, Ingelheim amRhein, Germany, 17University of Florence, Florence, Italy, 18Integrated BioBank of Luxembourg, Dudelange, Luxembourg |
| 09:20 – 09:30 O4-6 |
“Comparison of circulating tumor cell derived DNA and circulating cell-free DNA from simultaneous blood sampling of patients with metastatic breast cancer” Minetta C. Liu1,2; Keegan E. Haselkorn3; Karthik V. Giridhar1, 1Department of Oncology; Mayo Clinic, Rochester, MN, USA, 2Department of Laboratory Medicine and Pathology; Mayo Clinic, Rochester MN, USA, 3Medical Genome Facility; Mayo Clinic, Rochester, MN, USA |
| 09:30 – 12:00 |
PLENARY LECTURE SESSION 7 CIRCULATING TUMOR DNA TECHNOLOGIES AND APPLICATIONS IN CLINICAL PRACTICE Chairing: Michael Speicher & Nickolas Papadopoulos
|
| 09:30 – 10:00 PL7-1 |
“Novel mutation and InDel enrichment technologies for the analysis ofclinically relevant DNA alterations in circulating-DNA” Mike Makrigiorgos, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA |
| 10:00 – 10:30 PL7-2 |
“Implementation of plasma ctDNA testing into standard care – where weare and what we need from an EQA providers’ perspective” Verena Hasselmann, University of Heidelberg, Mannheim, Germany |
| 10:30 – 11:00 |
POSTER VIEWING SESSION AND NETWORKING COFFEE BREAK
|
| 11:00 – 11:30 PL7-3 |
“Epigenetic signatures in cell-free DNA” Michael Speicher, Medical University of Graz, Austria |
| 11:30 – 12:00 PL7-4 |
“Applications of liquid biopsies in the early detection of cancer.” Nicholas Papadopoulos, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA |
| 12:00 – 12.30 PL7-5 |
“Development, standardization and clinical evaluation of molecularassays in liquid biopsies” Evi Lianidou, University of Athens, Athens, Greece |
| 12:30 – 13:00 PL7-6 |
“Regulatory Considerations for Utilizing Liquid Biopsies in Drug and Diagnostics Development” Garry Kelloff, M.D., Special Advisor, CIP, DCTD, National Cancer Institute, NIH, USA |
| 12:30 – 13:00 |
TRAVEL AWARDS BEST POSTER AWARDS CLOSING REMARKS – END OF THE MEETING
|
| 13:30 – 20:00 |
CORFU TOWN SIGHTSEEING (OPTIONAL)
|
